No photo of Harry Hendrikse

View Scopus Profile

Harry Hendrikse

PROF.DR., (Principal Investigator)

 https://orcid.org/0000-0001-8072-5391
19962020

Research output per year

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

177Lutetium PSMA-radioligandtherapie bij prostaatkanker

Translated title of the contribution: 177Lutetium PSMA radioligand therapy in prostate cancer Vis, A. N., Jansen, B. H. E., Bodar, Y. J. L., Nieuwenhuijzen, J. A., Hendrikse, H. N. & Oprea-Lager, D. E., 14 Jan 2020, In : Tijdschrift voor Urologie.

Research output: Contribution to journal › Article › Professional

Open Access

ABCG2- and ABCB1 Inhibition Using Supratherapeutic Doses of Erlotinib: Clinical Implications in the Treatment of Central Nervous System Metastases

van de Stadt, E. A., Yaqub, M., Bahce, I. & Hendrikse, N. H., 1 Feb 2020, In : Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 61, 2, p. 305 1 p.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer

Huisman, M., Niemeijer, A-L., Windhorst, B., Schuit, R., Leung, D., Hayes, W., Poot, A., Bahce, I., Radonic, T., Oprea-Lager, D., Hoekstra, O., Thunnissen, E., Hendrikse, H., Smit, E., De Langen, J. & Boellaard, R., 14 Feb 2020, In : Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Research output: Contribution to journal › Article › Academic › peer-review

Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer

Jansen, B. H. E., Cysouw, M. C. F., Vis, A. N., van Moorselaar, R. J. A., Voortman, J., Bodar, Y. J. L., Schober, P. R., Hendrikse, N. H., Hoekstra, O. S., Boellaard, R. & Oprea-Lager, D. E., 10 Jan 2020, In : Journal of Nuclear Medicine. p. jnumed.119.236075

Research output: Contribution to journal › Article › Academic › peer-review

Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake

van de Stadt, E., Yaqub, M., Poot, A., Schuit, R., Bahce, I., Smit, E. & Hendrikse, H., 1 May 2019, In : Journal of Nuclear Medicine. 60

Research output: Contribution to journal › Meeting Abstract › Academic